Skip to main content

Relapsed/Refractory Myelofibrosis clinical trials at UCSF

1 research study open to eligible people

Showing trials for
  • A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies

    open to eligible people ages 18 years and up

    This is a Phase 1 cohort, dose-escalation, dose-expansion study of PRT543 in patients with advanced cancers who have exhausted available treatment options. The purpose of this study is to define a safe dose and schedule to be used in subsequent development of PRT543.

    San Francisco, California and other locations

Last updated: